Stay updated on XEN1101 Safety/Tolerability/PK in Single/Multiple Ascending Doses Clinical Trial
Sign up to get notified when there's something new on the XEN1101 Safety/Tolerability/PK in Single/Multiple Ascending Doses Clinical Trial page.

Latest updates to the XEN1101 Safety/Tolerability/PK in Single/Multiple Ascending Doses Clinical Trial page
- Check3 days agoChange DetectedThe history now shows a new version entry: Revision v3.4.3. The previous Revision v3.4.2 has been removed.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check31 days agoChange DetectedRevision: v3.4.2 was added to the history, updating the record's published version information. The deletions include the funding-lapse notice and the earlier revision entry (v3.4.1).SummaryDifference0.9%

- Check39 days agoChange DetectedA site-wide notice about government funding and operations has been added, and the history now shows Revision: v3.4.1, replacing Revision: v3.4.0.SummaryDifference0.9%

- Check46 days agoChange DetectedUI updates include a glossary toggle, green highlights for additions and red highlights for deletions in the history view, and an updated revision label to v3.4.0. These changes are focused on labeling and presentation rather than core study data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference1%

- Check60 days agoChange DetectedThe Record History shows a new revision entry (v3.3.4) added and the previous v3.3.3 entry removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check81 days agoChange DetectedNew revision entry v3.3.3 was added to the history. Entries for HHS Vulnerability Disclosure and Revision: v3.3.2 were removed.SummaryDifference0.2%

Stay in the know with updates to XEN1101 Safety/Tolerability/PK in Single/Multiple Ascending Doses Clinical Trial
Enter your email address, and we'll notify you when there's something new on the XEN1101 Safety/Tolerability/PK in Single/Multiple Ascending Doses Clinical Trial page.